UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

The Lancet (British edition), 2009-01, Vol.373 (9659), p.240-249

2009

Volltextzugriff (PDF)

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

The Milbank quarterly, 2017-09, Vol.95 (3), p.554-601

2017

Volltextzugriff (PDF)

Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications

Pharmacotherapy, 2017-01, Vol.37 (1), p.71-84

2017

Volltextzugriff (PDF)

Biopharmaceutical benchmarks 2010

Nature biotechnology, 2010-09, Vol.28 (9), p.917-924

Walsh, Gary

2010

Volltextzugriff (PDF)

A “Method of Use” to Prevent Generic and Biosimilar Market Entry

The New England journal of medicine, 2023-02, Vol.388 (6), p.483-485

2023

Volltextzugriff (PDF)

Medicare’s Plan for Drug-Price Negotiation — The Importance of Defining Generic Entry

The New England journal of medicine, 2023-07, Vol.389 (2), p.97-100

2023

Volltextzugriff (PDF)

High-Cost Generic Drugs — Implications for Patients and Policymakers

The New England journal of medicine, 2014-11, Vol.371 (20), p.1859-1862

2014

Volltextzugriff (PDF)

Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases

BMJ (Online), 2019-11, Vol.367, p.l6015

2019

Volltextzugriff (PDF)

Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access

JAMA internal medicine, 2021-04, Vol.181 (4), p.423

2021

Volltextzugriff (PDF)

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement

Health economics, 2015-02, Vol.24 (2), p.238-252

2015

Volltextzugriff (PDF)

Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration

The Lancet (British edition), 2013-02, Vol.381 (9867), p.680-689

2013

Volltextzugriff (PDF)

Biosimilars: How Can Payers Get Long-Term Savings?

PharmacoEconomics, 2016-06, Vol.34 (6), p.609-616

2016

Volltextzugriff (PDF)

Generics and Biosimilars: Barriers and Opportunities

Mayo Clinic proceedings, 2021-12, Vol.96 (12), p.2947-2957

2021

Volltextzugriff (PDF)

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1268-1272

2017

Volltextzugriff (PDF)

Decline in economic returns from new drugs raises questions about sustaining innovations

Health Affairs, 2015-02, Vol.34 (2), p.245-252

2015

Volltextzugriff (PDF)

New Math on Drug Cost-Effectiveness

The New England journal of medicine, 2015-11, Vol.373 (19), p.1797-1799

Bach, Peter B

2015

Volltextzugriff (PDF)

The Shortage of Essential Chemotherapy Drugs in the United States

The New England journal of medicine, 2011-11, Vol.365 (18), p.1653-1655

2011

Volltextzugriff (PDF)

Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP)

PloS one, 2017-05, Vol.12 (5), p.e0177770-e0177770

2017

Volltextzugriff (PDF)

Drug Regulation and Pricing — Can Regulators Influence Affordability?

The New England journal of medicine, 2016-05, Vol.374 (19), p.1807-1809

2016

Volltextzugriff (PDF)

Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers

Health Affairs, 2015-02, Vol.34 (2), p.294-301

2015

Volltextzugriff (PDF)

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals

PloS one, 2015-10, Vol.10 (10), p.e0140708-e0140708

2015

Volltextzugriff (PDF)

Availability, prices and affordability of essential medicines in Zhejiang Province, China

PloS one, 2020-11, Vol.15 (11), p.e0241761-e0241761

2020

Volltextzugriff (PDF)

Drug Shortages — A Critical Challenge for the Generic-Drug Market

The New England journal of medicine, 2011-12, Vol.365 (23), p.2147-2149

Chabner, Bruce A

2011

Volltextzugriff (PDF)

Reasons for allowing and refusing generic substitution and factors determining the choice of an interchangeable prescription medicine: a survey among pharmacy customers in Finland

BMC health services research, 2020-02, Vol.20 (1), p.82-82, Article 82

2020

Volltextzugriff (PDF)

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

Applied health economics and health policy, 2018-10, Vol.16 (5), p.653-660

2018

Volltextzugriff (PDF)

1 – 25 von 1.634

Suche als RSS-Feed

Aktive Filter

ThemaPharmaceutical Industry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(863)
Mit Volltextzugriff
(1.092)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Business Wire
(53)
Bmj
(51)
M2 Presswire
(43)
Pr Newswire
(39)
Drug Store News
(34)
The Lancet
(32)
Chain Drug Review
(31)
The New England Journal Of Medicine
(30)
Health Affairs
(28)
Pharmaceutical Technology
(27)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications

Biopharmaceutical benchmarks 2010

A “Method of Use” to Prevent Generic and Biosimilar Market Entry

Medicare’s Plan for Drug-Price Negotiation — The Importance of Defining Generic Entry

High-Cost Generic Drugs — Implications for Patients and Policymakers

Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases

Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement

Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration

Biosimilars: How Can Payers Get Long-Term Savings?

Generics and Biosimilars: Barriers and Opportunities

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries

Decline in economic returns from new drugs raises questions about sustaining innovations

New Math on Drug Cost-Effectiveness

The Shortage of Essential Chemotherapy Drugs in the United States

Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP)

Drug Regulation and Pricing — Can Regulators Influence Affordability?

Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals

Availability, prices and affordability of essential medicines in Zhejiang Province, China

Drug Shortages — A Critical Challenge for the Generic-Drug Market

Reasons for allowing and refusing generic substitution and factors determining the choice of an interchangeable prescription medicine: a survey among pharmacy customers in Finland

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review

Aktive Filter

Suchergebnisse filtern